Thymosin Alpha-1 (Thymalfasin): A Research Overview

Thymosin alpha-1 is the immune-modulating member of the thymosin family, and one of the better-evidenced compounds in this library: a thymus-derived peptide with decades of clinical use and regulatory approval in dozens of countries — though, importantly, not full approval in the United States. It is frequently confused with thymosin beta-4 (TB-500) because of the shared “thymosin” name, but the two do entirely different things. An honest overview conveys its genuine clinical standing, its specific US status, and the clear distinction from its tissue-repair namesake.

This overview summarizes what the published literature and regulatory record report about thymosin alpha-1 — its structure, mechanism, evidence, and status. It describes findings as they appeared in their study systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Thymosin Alpha-1 Is

Thymosin alpha-1 (Tα1; synthetic name thymalfasin) is a 28-amino-acid peptide derived from prothymosin alpha, a larger precursor that thymic epithelial cells process and release. It is heavily acidic (rich in aspartate and glutamate), giving it a net negative charge at physiological pH (Goldstein et al., isolation & sequence, 1977). It is marketed as the drug Zadaxin (SciClone Pharmaceuticals), typically a 1.6 mg subcutaneous injection.

A key distinction up front: thymosin alpha-1 and thymosin beta-4 (TB-500) share only their organ of origin. Tα1 is a 28-amino-acid immune modulator; thymosin beta-4 is a larger (43-amino-acid) tissue-repair peptide working on actin dynamics. Same family name, fundamentally different biology (Dominari et al., comprehensive review, World J Virol 2020).

Mechanism — Immune Modulation

Thymosin alpha-1 acts on the immune system. It modulates Toll-like receptor (TLR) signaling — activating dendritic cells through the MyD88-dependent pathway — promotes maturation and differentiation of T-lymphocytes (favoring a Th1 cellular immune response), and enhances natural killer (NK) cell activity (TLR/dendritic-cell mechanism review (Dominari 2020)). The practical theme across this work is the restoration of immune function in states of impairment — chronic infection, immunosuppression, and as an adjunct in cancer care.

The Evidence Base — Substantial

Thymosin alpha-1 has a comparatively deep clinical literature and has been used clinically since the 1990s. It is approved in 30+ countries (as Zadaxin), primarily for hepatitis B and C and as an immune adjunct in cancer patients, with completed trials including Phase II in hepatitis B and Phase III work in hepatitis C (approvals & clinical-trial history (Dominari 2020)). Peer-reviewed studies have examined Tα1 as an immune-modulating adjunct in settings such as infections in immunocompromised patients (clinical immune-adjunct study example). Among this library’s compounds, there is a relatively strong evidence base, with the crucial caveat that this approval and evidence are concentrated outside the United States. Notably, the largest controlled test to date — the Phase 3 TESTS sepsis trial (BMJ, 2025; 1,106 patients) — did not meet its primary endpoint, a reminder that breadth of use does not equal proven benefit in every studied setting.

• 28-amino-acid immune modulator (thymalfasin/Zadaxin); acts via TLR/dendritic-cell and T-cell pathways.
• Approved in 30+ countries (hepatitis B/C, cancer immune adjunct); used clinically since the 1990s.
• Distinct from thymosin beta-4 (TB-500) — immune modulation, not tissue repair.

Safety Considerations

In its approved indications, thymosin alpha-1 has decades of clinical safety data and is generally well tolerated, with minimal side effects. As an immunomodulator, it is considered in relation to immune activation; it is used in clinical practice under medical supervision in countries where it is approved. As always, research-grade material is distinct from the approved Zadaxin product and carries the usual purity/handling uncertainties of unregulated peptides.

Regulatory Status

The status below reflects mid-2026 and may change; verify against current FDA notices before relying on it. Thymosin alpha-1 is not approved as a finished drug in the United States, Japan, or most of Europe, despite its approval in 30+ other countries; in the US, it holds FDA orphan-drug designations for certain conditions (e.g., chronic hepatitis B, malignant melanoma, DiGeorge anomaly, hepatocellular carcinoma), but that is not the same as marketing approval. US access has been limited to clinical trial or compassionate use channels. Its 503A peptide-compounding status has been unsettled — it was removed from the FDA’s Category 2 list in 2024 pending further review. Research-grade material is sold for laboratory use only and is, by its labeling, not for human consumption.

Why Thymosin Alpha-1 Draws Research Interest

Thymosin alpha-1 is a well-characterized immune modulator with real, multi-decade clinical use and broad international approval — of strong interest in infection, oncology-adjunct, and immune-restoration research. The accurate framing is a clinically established immune peptide approved in many countries but not the US, with genuine trial evidence, orphan (not marketing) US designations, an unsettled compounding status, and a biology entirely distinct from its tissue-repair namesake.

For deeper reading, the cited literature is the best starting point. Thymosin alpha-1 is most usefully contrasted with its family namesake — see the Thymosin Beta-4 / TB-500 overview. The wider class is collected in our peptide research library.